CA Patent

CA2551182C — Novel kappa receptor selective opioid peptides

Assigned to Torrey Pines Institute for Molecular Studies · Expires 2010-08-24 · 16y expired

What this patent protects

The present invention provides novel opioid peptides which are selective for the kappa opiate receptor. In one embodiment, the kappa-selective opioid peptides have the general structure Ac-Al-B2-C3-Arg-Tyr-Arg-Tyr-Arg-Arg-Arg-NH2, (SEQ ID NO. 28), wherein Al is Tyr or Arg, B2 is …

USPTO Abstract

The present invention provides novel opioid peptides which are selective for the kappa opiate receptor. In one embodiment, the kappa-selective opioid peptides have the general structure Ac-Al-B2-C3-Arg-Tyr-Arg-Tyr-Arg-Arg-Arg-NH2, (SEQ ID NO. 28), wherein Al is Tyr or Arg, B2 is Arg or Phe, and C3 is Thr, Phe, or Met. In yet other embodiments, the kappa-selective opioid peptides have the general structure (D)Phe-D4-E5-F6 (SEQ ID NO. 29) or (D)Nle-D4-E5-F6 (SEQ ID NO. 30), where in both of these formulae D4 is (D)NapAla or (D)Phe, E5 is (D)Nle, Trp, or (D)Ile, and F6 is (D)Arg or (D)ChAla.

Drugs covered by this patent

Patent Metadata

Patent number
CA2551182C
Jurisdiction
CA
Classification
—
Expires
2010-08-24
Drug substance claim
No
Drug product claim
No
Assignee
Torrey Pines Institute for Molecular Studies
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.